Uncategorized
European Commission approves Actemra/RoActemra for giant cell arteritis
Actemra/RoActemra has been approved by the European Commission for the treatment of giant cell arteritis, according to a Roche press release.The anti-IL-6 receptor biologic Actemra/RoActemra (tocilizumab) was approved for giant cell arteritis (GCA) based on the outcome of the GiACTA phase 3 randomized, double-masked, placebo-controlled trial, the release said. In the trial, Actemra/RoActemra combined with a 6-month steroid taper significantly increased the number of patients who had sustained remission at 1 year (56%) compared with a 6-month steroid taper alone (14%) (P < .0001).